Inventor · disambiguated record
Raphael Darteil
Also filed as: DARTEIL RAPHAEL · DARTEIL RAPHAEL JEAN · DARTEIL RAPHAËL
25 granted patents·18 pending applications·232 citations·filing 1995–2024
96Inventor score
Top patents by PatentIndex Score
43 records- 0193US9221751B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2014·Granted Dec 29, 2015·9 cites·21 claims
- 0292US8772342B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersDARTEIL RAPHAEL·Filed 2010·Granted Jul 8, 2014·39 cites·11 claims
- 0391US9585853B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2015·Granted Mar 7, 2017·4 cites·15 claims
- 0490US9782373B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2017·Granted Oct 10, 2017·3 cites·6 claims
- 0588US10350181B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2018·Granted Jul 16, 2019·2 cites·19 claims
- 0688US5980906ALive recombinant avian vaccine using an avian herpesvirus as vectorMERIAL SAS·Filed 1995·Granted Nov 9, 1999·77 cites·29 claims
- 0786US8895619B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2014·Granted Nov 25, 2014·8 cites·11 claims
- 0885US12030861B1L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereofENYO PHARMA·Filed 2023·Granted Jul 9, 2024·2 cites·48 claims
- 0980US10905680B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2018·Granted Feb 2, 2021·1 cites·18 claims
- 1080US6045803ALive recombinant avian vaccine using an avian herpesvirus as vectorMERIAL SAS·Filed 1999·Granted Apr 4, 2000·41 cites·17 claims
- 1178US10130613B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 20, 2018·1 cites·10 claims
- 1278US10130612B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 20, 2018·1 cites·11 claims
- 1378US10117856B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 6, 2018·1 cites·10 claims
- 1478US10117855B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 6, 2018·1 cites·14 claims
- 1574US2024410010A1Non-invasive diagnostic of non-alcoholic steatohepatitisGENFIT·Filed 2024·Application pending·0 cites
- 1673US11103484B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2020·Granted Aug 31, 2021·0 cites·8 claims
- 1773US6358512B1Feline infectious peritonitis vaccineMERIAL SAS·Filed 2000·Granted Mar 19, 2002·3 cites·10 claims
- 1869US10022343B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2017·Granted Jul 17, 2018·0 cites·10 claims
- 1967US5733554AAvian herpesvirus-based live recombinant avian vaccine, in particular against Gumboro diseaseRHONE MERIEUX·Filed 1995·Granted Mar 31, 1998·22 cites·13 claims
- 2066US2025019358A1L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereofENYO PHARMA·Filed 2024·Application pending·0 cites
- 2165US2019000813A1Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2018·Application pending·0 cites
- 2261US7253296B2Acylated aminopropanediols and analogues and therapeutic uses thereofGENFIT·Filed 2004·Granted Aug 7, 2007·1 cites·33 claims
- 2361US2017290812A1Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Application pending·0 cites
- 2460US2022411874A1Methods for diagnosing and evaluating non-alcoholic steatohepatitisGENFIT·Filed 2022·Application pending·0 cites
- 2559US10722575B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2019·Granted Jul 28, 2020·0 cites·12 claims
- 2657US2020384105A1Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2020·Application pending·0 cites
- 2756US2024216364A1Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatmentENYO PHARMA·Filed 2022·Application pending·0 cites
- 2856US2025019370A1L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereofENYO PHARMA·Filed 2024·Application pending·0 cites
- 2952US2023165853A1Method for treating chronic kidney diseasesENYO PHARMA·Filed 2022·Application pending·0 cites
- 3052US2023060715A1Use of fxr agonists for treating an infection by hepatitis d virusINST NAT SANTE RECH MED·Filed 2021·Application pending·0 cites
- 3151US12104209B2Non-invasive diagnostic of non-alcoholic steatohepatitisGENFIT·Filed 2017·Granted Oct 1, 2024·0 cites·11 claims
- 3251US2006154984A1Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereofDARTEIL RAPHAEL·Filed 2004·Application pending·0 cites
- 3351US2024100125A1Synergistic effect of a fxr agonist and ifn for the treatment of hbv infectionENYO PHARMA·Filed 2022·Application pending·0 cites
- 3451US2023321033A1Thiophen compounds for use in the treatment of renal fibrosisENYO PHARMA·Filed 2021·Application pending·0 cites
- 3550US2006252827A1Therapeutic use of of acyglycerols and the nitrogen-and sulphur-containing analogues thereofDARTEIL RAPHAEL·Filed 2004·Application pending·0 cites
- 3650US2024156778A1Thiophene derivatives for use in treating portal inflammation and fibrosisENYO PHARMA·Filed 2020·Application pending·0 cites
- 3749US2004038249A1Inducible expression systems employing PPAR transcriptional activatorsFiled 2003·Application pending·0 cites
- 3848US11371098B2Methods for diagnosing and evaluating non-alcoholic steatohepatitisGENFIT·Filed 2016·Granted Jun 28, 2022·0 cites·2 claims
- 3947US5676952AHerpesviruses transformed to express GD in vitroRHONE MERIEUX·Filed 1995·Granted Oct 14, 1997·8 cites·24 claims
- 4044US2022313690A1Synergistic effect of eyp001 and ifn for the treatment of hbv infectionENYO PHARMA·Filed 2020·Application pending·0 cites
- 4143US6080850AFeline infectious peritonitis vaccineMERIAL SAS·Filed 1995·Granted Jun 27, 2000·4 cites·8 claims
- 4243US2022241376A1Method for decreasing adverse-effects of interferonENYO PHARMA·Filed 2020·Application pending·0 cites
- 4338US6096535AFeline infectious peritonitis vaccineMERIAL SAS·Filed 1998·Granted Aug 1, 2000·4 cites·14 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →